https://www.selleckchem.com/pr....oducts/ziritaxestat.
Patients with a history of myocardial infarction (MI) are at very high risk of subsequent cardiovascular events. This study evaluated the association of treatment intensity and adherence to lipid-lowering therapies (LLT) with major adverse cardiovascular events (MACE) among post-MI patients in Germany. We carried out a retrospective cohort study using German health claims data (2010-2015). We included patients≥18years, with a history of MI and who started an LLT (statin and/or ezetimibe), between 2011 and 2013. The follow-up period
Like
Comment
Share
